Comparative Pharmacology
Head-to-head clinical analysis: CLARISCAN versus PROHANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARISCAN versus PROHANCE.
CLARISCAN vs PROHANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gadoteridol is a paramagnetic gadolinium-based contrast agent (GBCA) that shortens T1 and T2 relaxation times in tissues, enhancing signal intensity in magnetic resonance imaging (MRI).
Gadolinium-based paramagnetic contrast agent that enhances T1-weighted MRI signal by shortening the longitudinal relaxation time of water protons.
0.1 mL/kg (0.2 mmol/kg) intravenous bolus, up to 20 mL.
0.1 mmol/kg (0.2 mL/kg) intravenous bolus; not to exceed 0.1 mmol/kg for single dose; may repeat once within 30 minutes for certain indications.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (normal renal function); prolonged to 10-30 hours in severe renal impairment (creatinine clearance <30 mL/min).
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function; increases to 4–12 hours in moderate to severe renal impairment; correlates with creatinine clearance.
Renal: 95% as unchanged drug; biliary/fecal: 5%.
Primarily renal (glomerular filtration), with >95% of the administered dose excreted unchanged in urine within 24 hours; less than 1% fecal or biliary.
Category C
Category C
Gadolinium-Based Contrast Agent
Gadolinium-Based Contrast Agent